Hepatitis C

World Hepatitis Day 2025: Hepatitis is a major health threat globally. Chronic hepatitis B and C cause silent liver damage and cancer. However, these are preventable, treatable, and in C’s case, curable. Here's everything you need to know about the history, theme, significance and preventive tips of this day.

Hepatitis in India: Most common type, causes, long-term effects, and tips to keep liver healthy

World Hepatitis Day 2024: Because of poor sanitation, hepatitis is common in India, especially hepatitis E. Hepatitis B and C can have serious repercussions, such as chronic liver disease, cirrhosis, and liver cancer, whereas hepatitis A and E usually do not cause long-term health issues.

World Hepatitis Day 2024: Prevent liver damage due to viral Hepatitis with these lifestyle changes

World Hepatitis Day: Severe diseases like cirrhosis, liver failure, and liver cancer can result from hepatitis-related liver damage. It's imperative to take lifestyle changes and preventative steps to avoid liver damage from viral hepatitis because of the serious side effects.

Cholera, hepatitis A, other waterborne illnesses: Symptoms, prevention strategies you must know

Symptoms of waterborne illnesses: Though vital for life, water can also be a source of illness if not properly managed. Pathogens in contaminated water can cause severe health issues. Here are some practical ways to safeguard yourself and your family from waterborne illnesses.

Pregnancy complications: Risks of Hepatitis A, B, and C, how to prevent inflammation of liver

Pregnant women need to understand the risks of hepatitis A, B, and C to keep both moms and babies healthy. Engaging in workshops, seminars, and prenatal care classes can empower women with the knowledge to protect themselves and their babies from these infections.

Jaundice causes, symptoms, cure: Watch out for these warning signs of a serious, underlying condition

Jaundice, often a sign rather than a disease, results from bilirubin accumulation in the skin and eyes. Some people may experience fever, chills, abdominal pain, the presence of fluid in the abdomen, flu-like symptoms and even clay-like faeces. Here's everything you need to know about its causes, symptoms, and the ways to prevent it.

Coronavirus pandemic | Hepatitis C drugs may help fight COVID-19, supercomputer simulations suggest

Researchers found that compounds from the four hepatitis C drugs have high affinity to bind SARS-CoV-2 very strongly and may, therefore, be able to prevent infection.

Hepatitis C drug effective against Zika virus: Study

The repurposed drug effectively protected and rescued neural cells infected by the Zika virus - and blocked transmission of the virus to mouse foetuses, according to findings.

Natco launches generic Hepatitis C drug Velpanat in Nepal

The Hyderabad-based firm has signed a non-exclusive licensing agreement with Gilead Sciences Inc, to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.

Laurus Labs expects revenue generation to begin in FY18

The company expects healthy growth going ahead, according to Ravi Kumar, ED and CFO of Laurus Labs, adding that its total debt post the IPO will stand at Rs 750 crore

IPO funds to be used for long-term debt repayment: Laurus Labs

The company is looking to raise Rs 330 crore of which Rs 225 crore will be used to finance long-term debt and rest for corporate purposes, said Satyanarayana Chava, founder & CEO of the company.

Laurus Labs IPO opens: Analysts bullish but say valuations high

The leading player in developing generic Active Pharmaceutical Ingredients (APIs) aims to utilise the net proceeds from the fresh issue towards pre-payment of term loans and general corporate purposes.

Biocon Initiates "EK Prayaas" Nationwide Awareness Program on Hepatitis C

Biocon Branded Formulations business announced the launch of a new patient support program “Ek Prayaas” through a ...

Hepatitis C, HIV spread on the back of drug abuse in Punjab

In the fourth part of CNBC-TV18‘s series ‘What's ailing rural India‘, Archana Shukla reports that the state's healthcare machinery is simply not equipped to deal with the challenge.

What's ailing rural India: Hepatitis C menace hits Punjab

In the third part of CNBC-TV18‘s series ‘What's ailing rural India‘, Archana Shukla reports from a village in Punjab which has earned the infamous tag of being the Hepatitis C capital of the state.

What‘s ailing rural India: Punjab's killer drug needles

In part II of our series ‘What's Ailing Rural India‘ from the state of Punjab, CNBC TV18's Archana Shukla reports on the rise of blood borne infections and why the government's attempt to tackle it is failing.

Cipla in pact with Russian firm for HIV, Hepatitis C drugs

"Today patients undergoing anti-HIV treatment have to take a lot of drugs every day. Our preparations will meet the expectations of Russian patients and will solve this problem," Nacimbio CEO Nikolay Semenov said.

Natco Pharma Q4 net up 11% at Rs 60 cr

The company had posted a net profit of Rs 54.44 crore for the January-March period of the previous fiscal.

NGO FIND, Cipla tie-up for Hepatitis C treatment in India

The new HCV therapies, which are relatively non-toxic compared to earlier interferon-based treatments, have a greater than 95 per cent cure rate over just 12-24 weeks of treatment. Older treatments took a year or more, and were much less effective.

Natco Pharma signs agreement for mfg, sale of hepatitis C drug

Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir to treat patients with chronic hepatitis C virus (HCV) genotype 3 infection.

Mylan launches generic Hepatitis C drug in India

"Mylan recognises the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus," Mylan President Rajiv Malik said.

Biocon introduces advanced therapy to treat Hepatitis C

CIMIVIR-L, a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, will be made available to patients in India at a fraction of the global cost of the innovator brand, Biocon Ltd said in a statement.

Strides Shasun gets DCGI nod to make Hepatitis C drug

The company has received approval for manufacturing a generic version of Sofosbuvir 400 mg, Strides Shasun today said in a filing to BSE. Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.

Natco gets DCGI nod to launch hepatitis C drug in India

“The company has received approval for the generic version of ledipasvir + sofosbuvir combination from Drugs Controller General (India)”, Natco Pharma said in a BSE filing today.

Expect FY17 topline to grow 20% on back of new drug: Omkar

Omkar Speciality Chemicals' whole time director Omkar P Herlekar is confident of logging a growth rate above industry standards for FY16.